Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models

Human Gene Therapy

Volumn 25, Issue 2, 2014, Pages 121-131

  Aurisicchio, Luigi ^a,e   Peruzzi, Daniela ^a,f   Koo, Gloria ^b   Wei, Wei Zen ^c   La Monica, Nicola ^a,g   Ciliberto, Gennaro ^d  

^a IRBM   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Grande Ospedale Metropolitano   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Johnson and Johnson Innovation Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL TOXIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; PLASMID DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; GENE ORDER; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS; RATS; RECEPTOR, ERBB-2; VACCINES, DNA;

EID: 84893592971     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.103     Document Type: Article

References (38)

1. American Veterinary Medical Association (AVMA) Panel on Euthanasia. (2013). AVMA Guidelines for the Euthanasia of Animals. Available from: https://www.avma.org/KB/Policies/Documents/euthanasia.pdf
2. Aurisicchio, L., and Ciliberto, G. (2012). Genetic cancer vaccines: Current status and perspectives. Expert Opin. Biol. Ther. 12, 1043-1058.
3. Aurisicchio, L., and Ciliberto, G. (2011a). Emerging cancer vaccines: The promise of genetic vectors. Cancers 3, 3687-3713.
4. Aurisicchio, L., and Ciliberto, G. (2011b). Harnessing the immune system to fight cancer: The promise of genetic cancer vaccines. In Current Cancer Treatment: Novel Beyond Conventional Approaches. Ö ner Ö zdemir, ed. (InTech, Rijeka, Croatia) Chapter 16.
5. Camacho, R.E., Wnek, R., Fischer, P., et al. (2007). Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLADRB1 01 transgene: A model of SCID-hu mouse for vaccine development. Exp. Hematol. 35, 1219-1230.
6. Cheever, M.A., and Higano, C.S. (2011). PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520-3526.
7. Cipriani, B., Fridman, A., Bendtsen, C., et al. (2008). Therapeutic vaccination halts disease progression in BALB/NeuT mice: The amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene Ther. 19, 670-680.
8. Clarke, P., Mann, J., Simpson, J.F., et al. (1998). Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58, 1469-1477.
9. Colloca, S., Barnes, E., Folgori, A., et al. (2012). Vaccine vectors derived for a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, 115ra2.
10. Conforti, A., Peruzzi, D., Giannetti, P., et al. (2009). A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J. Immunother. 32, 744-754.
11. Dharmapuri, S., Peruzzi, D., and Aurisicchio, L. (2009). Engineered Ad serotypes for overcoming anti-vector immunity [review]. Expert Opin. Biol. Ther. 9, 1279-1287.
12. Diaz, C.M., Chiappori, A., Aurisicchio, L., et al. (2013). Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J. Transl. Med. 11, 62.
13. Disis, M.L., Knutson, K.L., Schiffman, K., et al. (2000). Preexistent immunity to the HER2/neu oncogenic protein in patients with HER2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat. 62, 245-252.
14. Eades-Perner, A.M., van der Putten, H., Hirth, A., et al. (1994). Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 54, 4169-4176
15. Facciabene, A., Aurisicchio, L., Elia, L., et al. (2007). Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 26, 47-58.
16. Fridman, A., Finnefrock, A.C., Peruzzi, D., et al. (2012). An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. Oncoimmunology 1, 1258-1270.
17. Gallo, P., Dharmapuri, S., Nuzzo, M., et al. (2005). Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int. J. Cancer 113, 67-77.
18. Gallo, P., Dharmapuri, S., Nuzzo, M., et al. (2007). Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/NeuT transgenic mice. Int. J. Cancer 120, 574-584.
19. Giannetti, P., Facciabene, A., La Monica, N., and Aurisicchio, L. (2006). Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J. Immunol. Methods 316, 84-96.
20. Hammarström, S. (1999). The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67-81.
21. Hance, K.W., Zeytin, H.E., and Greiner, J.W. (2005). Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccines. Mutat. Res. 576, 132-154.
22. Ilantzis, C., DeMarte, L., Screaton, R.A., and Stanners, C.P. (2002). Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 4, 151-163.
23. Impellizeri, J.A., Ciliberto, G., and Aurisicchio, L. (2012). Electrogene-transfer as a new tool for cancer immunotherapy in animals. Vet. Comp. Oncol. [Epub ahead of print] DOI: 10.1111/vco.12006.
24. Lindau, D., Gielen, P., Kroesen, M., et al. (2012). The immunosuppressive tumor network: MDSCs, Tregs and NKT cells. Immunology 138, 105-115.
25. Lu, S. (2009). Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346-351.
26. Lucchini, F., Sacco, M.G., Hu, N., et al. (1992). Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett. 64, 203-209.
27. Mennuni, C., Calvaruso, F., Facciabene, A., et al. (2005). Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117, 444-455.
28. Moertel, C.G., Fleming, T.R., Macdonald, J.S., et al. (1993). An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270, 943-947.
29. Nagorsen, D., Keilholz, U., Rivoltini, L., et al. (2000). Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, HER2/neu and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 60, 4850-4854.
30. Piechocki, M.P., Ho, Y.S., Pilon, S., and Wei, W.Z. (2003). Human ErbB-2 (Her-2) transgenic mice: A model system for testing Her-2 based vaccines. J. Immunol. 171, 5787-5794.
31. Rentzsch, C., Kayser, S., Stumm, S., et al. (2003). Evaluation of pre-existent immunity in patients with primary breast cancer: Molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin. Cancer Res. 9, 4376-4386.
32. Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235, 177-182.
33. Stark, A., Hulka, B.S., Joens, S., et al. (2000). HER2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 18, 267-274.
34. Turriziani, M., Fantini, M., Benvenuto, M., et al. (2012). Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. Recent Pat. Anticancer Drug Discov. 7, 265-296.
35. U.K. Coordinating Committee on Cancer Research. (1998). UKCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer 58, 109-113.
36. Vasconcelos, J.R., Dominguez, M.R., Araú jo, A.F., et al. (2012). Relevance of long-lived CD8+ T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front. Immunol. 3, 358.
37. Woodland, D.L. (2004). Jump-starting the immune system: Prime-boosting comes of age. Trends Immunol. 25, 98-104.
38. Zhou, B.P., and Hung, M.C. (2003). Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin. Oncol. 30, 38-48.